The second installment of A Brief Guide To Ukrainian Jazz—a series developed with the cooperation of the Ukrainian ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback